NASDAQ · SRPT
Healthcare · Biotechnology
$18.62
Down-$0.61 (-3.17%)
Updated Oct 31, 2026, 6:14 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SRPT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SRPT closed at $18.62 after 21 trading sessions, up 6.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $19.04 | $19.50 | $18.41 | $18.62 | 1.32M |
| Oct 29, 2026 | $19.195 | $19.6819 | $18.96 | $19.23 | 1.19M |
| Oct 28, 2026 | $18.77 | $19.33 | $18.50 | $19.32 | 1.36M |
| Oct 27, 2026 | $18.05 | $18.89 | $17.69 | $18.89 | 2.23M |
| Oct 26, 2026 | $17.77 | $18.14 | $17.655 | $17.98 | 1.36M |
| Oct 23, 2026 | $17.94 | $18.12 | $17.155 | $17.73 | 1.29M |
| Oct 22, 2026 | $18.40 | $18.9369 | $18.115 | $18.18 | 1.24M |
| Oct 21, 2026 | $19.05 | $19.30 | $18.49 | $18.56 | 2.03M |
| Oct 20, 2026 | $17.74 | $19.695 | $17.655 | $19.17 | 3.33M |
| Oct 19, 2026 | $17.25 | $17.83 | $17.12 | $17.73 | 2.33M |
| Oct 16, 2026 | $17.82 | $17.84 | $16.85 | $17.10 | 9.86M |
| Oct 15, 2026 | $16.96 | $17.955 | $16.61 | $17.79 | 4.04M |
| Oct 14, 2026 | $16.53 | $16.91 | $16.3675 | $16.83 | 2.74M |
| Oct 13, 2026 | $17.12 | $17.23 | $16.41 | $16.51 | 3.69M |
| Oct 12, 2026 | $17.88 | $18.14 | $17.30 | $17.44 | 3.28M |
| Oct 9, 2026 | $18.245 | $18.525 | $17.68 | $17.85 | 3.02M |
| Oct 8, 2026 | $17.275 | $18.28 | $17.20 | $18.21 | 3.52M |
| Oct 7, 2026 | $17.28 | $17.665 | $16.98 | $17.50 | 2.87M |
| Oct 6, 2026 | $17.60 | $17.65 | $17.04 | $17.31 | 2.69M |
| Oct 5, 2026 | $17.385 | $17.55 | $17.10 | $17.49 | 2.2M |
| Oct 2, 2026 | $17.75 | $17.76 | $17.21 | $17.50 | 2.55M |
The latest Smart Investors Daily articles mentioning SRPT.
Company
Market Activity
Research & News
SRPT research
Company profile and research snapshot.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Sector Perform | — |
| Oct 5, 2026 | HC Wainwright & Co. | Sell | — |
| Sep 30, 2026 | JP Morgan | Neutral | — |
| Sep 28, 2026 | Needham | Underperform | — |
| Jul 9, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 26, 2026
CAMBRIDGE, Mass., October 26, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:
Yahoo · Oct 23, 2026
For questions about this article or underlying research, email [email protected].
Yahoo · Oct 22, 2026
CAMBRIDGE, Mass., October 22, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026. Subsequently, at 4:30 p.m. ET, the Company will host a conference call to discuss these results.
Yahoo · Oct 16, 2026
Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares reached their highest close in a year on October 15, 2026, ending the session at $236.50. Investors paying that premium are betting the drugmaker is ready to grow again. To meet those expectations, its sales, nearly all from COVID vaccines, have to stop shrinking, while its newer vaccines and cancer drugs have to start selling. Has the business caught up with Moderna's share pri
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SRPT.
